The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...

Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...

Incyte recently reported positive topline results from its pivotal Phase 3 frontMIND trial, where adding tafasitamab (Monjuvi/Minjuvi) and lenalidomide to R-CHOP improved progression-free survival for ...

Incyte Corporation rated Buy on surging Hem/Onc growth, Monjuvi/Minjuvi catalysts, frontMIND data and strong cash. Click for ...

Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

US biotech Incyte (Nasdaq: INCY) yesterday announced positive top-line results from the pivotal Phase III frontMIND trial ...

Genmab shifts to innovation-led growth with 21% revenue, 52% operating profit, $3.4B cash, Epkinly, Rina-S, and Anthropic AI ...

UW researchers found potential new treatments for a rare pediatric brain cancer each year that has a median survival time of ...

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.

Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash ...